Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Intensive Care Med ; 36(11): 1264-1271, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-32772778

RESUMO

OBJECTIVE: The distribution of postoperative gastrointestinal (GI) dysfunction and its association with outcome were investigated in cardiac surgery patients. Gastrointestinal function was evaluated using the Acute Gastrointestinal Injury (AGI) grade proposed by the European Society of Intensive Care Medicine. DESIGN: Prospective observational study at a single center. SETTING: University hospital. PATIENTS: Consecutive patients presenting for elective cardiac surgery with extracorporeal circulation (ECC). INTERVENTIONS: None. RESULTS: Daily assessment using the AGI grade was performed on the first 3 postoperative days in addition to standard care. For analysis, 3 groups were formed based on the maximum AGI grade: AGI 0, AGI 1, and AGI ≥2. Five hundred and one patients completed the study; 32.7%, 65.1%, and 2.2% of the patients scored a maximum AGI 0, AGI 1, and AGI ≥2, respectively. Patients with AGI grade ≥2 had more frequently undergone thoracic aortic surgery and had longer surgery duration and time on ECC. Patients with AGI grade ≥2 had statistically significant higher frequency of GI complications within 30 days (63.6% vs 1.2% and 5.5% in patients with AGI 0 and AGI 1) and higher 30-day mortality (9.1% vs 0.0% and 1.8% in patients with AGI 0 and AGI 1). CONCLUSIONS: Early GI dysfunction following cardiac surgery was associated with an unfavorable outcome. Increased attention to GI dysfunction in cardiac surgery patients is warranted and the AGI grade could be a helpful adjunct to a structured approach.


Assuntos
Procedimentos Cirúrgicos Cardíacos , Gastroenteropatias , Procedimentos Cirúrgicos Cardíacos/efeitos adversos , Estado Terminal , Gastroenteropatias/epidemiologia , Gastroenteropatias/etiologia , Humanos , Unidades de Terapia Intensiva , Estudos Prospectivos
2.
Neurourol Urodyn ; 30(7): 1382-7, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21661032

RESUMO

AIMS: Beta3-adrenoceptor selective agonists are evaluated as a new treatment for patients with lower urinary tract symptoms . It is believed that ß3-AR selective agonists exert their effects via a peripheral site of action. However, ß3-ARs have been found in brain tissue. This study examined whether ß3-ARs are present in rat sacral spinal cord, and whether there are differences in ß3-AR expression between normal and partial urethral obstruction (PUO) animals, and furthermore assessed the functional relevance of spinal ß3-ARs for micturition. METHODS: Thirty-eight male Sprague-Dawley rats underwent either PUO or sham-operation. Two weeks after operation, half of the animals were used for histomorphological analysis. Remaining animals were used for functional experiments, where a ß3-AR selective agonist, BRL 37344, was given intrathecally. Bladder function was assessed by continuous cystometry in non-anesthetized animals before and after drug administration. RESULTS: Beta3-ARs were found in sacral spinal cord segments with an accumulation in the ventral horn. There was a significant increase of ß3-AR expression in obstructed rats. In functional experiments obstructed rats showed increased bladder weight, micturition frequency, spontaneous activity, and bladder pressures (all P < 0.05) compared to controls. Intrathecally administered BRL 37344 showed no effect in non-obstructed rats. In obstructed rats intrathecal BRL 37344 significantly reduced bladder pressures, spontaneous activity, and micturition frequency (all P < 0.05). CONCLUSIONS: Beta3-ARs are present in rat sacral spinal cord, and are significantly up-regulated after PUO. Besides their well-established peripheral site of action in the treatment of voiding dysfunction, ß3-AR selective agonists might exert relevant effects at a central nervous site of action.


Assuntos
Receptores Adrenérgicos beta 3/metabolismo , Medula Espinal/metabolismo , Obstrução Uretral/metabolismo , Bexiga Urinária/inervação , Micção , Agonistas de Receptores Adrenérgicos beta 3/administração & dosagem , Animais , Western Blotting , Modelos Animais de Doenças , Etanolaminas/administração & dosagem , Imuno-Histoquímica , Masculino , Projetos Piloto , Ratos , Ratos Sprague-Dawley , Sacro , Medula Espinal/efeitos dos fármacos , Medula Espinal/fisiopatologia , Fatores de Tempo , Regulação para Cima , Obstrução Uretral/tratamento farmacológico , Obstrução Uretral/fisiopatologia , Micção/efeitos dos fármacos , Urodinâmica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA